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Clinical eﬀectiveness of antibiotic therapy is dependent on the timely 
administration of in vitro active antibiotic therapy (appropriate therapy). 
In this observational study we ascertained the time to appropriate therapy 
and its eﬀect on 30-day survival in patients with BSIs caused by S. aureus or 
E. coli.
Methods
For this prospective cohort study patients were enrolled from thirteen 
tertiary care hospitals in as many European countries between June 2007 
and June 2008. The impact of appropriate therapy was analysed by survival 
analysis with appropriate therapy included as time-dependent variable. 
Results
In total, 763 and 1,028 patients with S. aureus and E. coli BSIs were included. 
In the S. aureus cohort, 91% patients received appropriate therapy, whereby 
patients with MSSA received appropriate therapy signiﬁcantly earlier (after 
a median of 4 hours) than patients with MRSA (after a median of 48 hours). 
In the E. coli cohort, 93% of the patients received appropriate therapy. 
Again, patients infected with SEC received appropriate therapy signiﬁcantly 
earlier (median 4 hours) than patients with resistant isolates (median 40 
hours). Compared to in vitro inactive antibiotic therapy, appropriate therapy 
signiﬁcantly reduced mortality in the MSSA (HR, 0.47) and SEC (HR, 0.38) 
cohort, but not in patients with resistant infections.
Conclusions
In European hospitals, time to appropriate therapy in patients with 
susceptible BSIs is short, improving survival. When infections are 
complicated by resistance, administration of appropriate therapy is often 






















Antimicrobial chemotherapy that is active against pathogens causing infections is 
essential for the success of modern medical interventions. The potential beneﬁcial 
eﬀect is, however, dependent on timely administration of the correct antibiotic 
compound. Lack or misjudgement of clinical symptoms of infection can lead to 
unwarranted delays in antibiotic treatment. At the same time, the range of possible 
etiological agents as well as antimicrobial resistance can even further protract the 
selection of a compound with the correct spectrum of activity. 
Time until administration of appropriate therapy could inﬂuence infection related 
mortality. This may in part explain why patients suﬀering from infections caused 
by antibiotic resistant bacteria experience higher mortality than patients infected 
with susceptible bacteria.1-4 We carried out the current investigation, in order 
to determine whether the prevalent antibiotic treatment practice in European 
tertiary care centres can explain the observed diﬀerences in survival between 
these groups of patients. 
When estimating the clinical impact of appropriate therapy in observational studies, 
treatment independent survival can lead to bias. Infected patients surviving for a 
longer period have a higher chance of receiving appropriate therapy than patients 
dying shortly after diagnosis. This is due to the fact that informed adjustment 
of antibiotic therapy can only take place after results from the microbiological 
laboratory have become available. This could lead to the foregone conclusion 
that patients receiving appropriate therapy have a better chance of survival even 
if therapy did not have an eﬀect. Time-to-event analysis can eliminate bias due 
to this potential spurious association between appropriate therapy and survival, 
known as immortal time bias.5
In this article we describe a prospective cohort study, in which we observed the 
time to administration of appropriate therapy and its eﬀect on 30 day survival for 




A prospective cohort study was carried out in thirteen tertiary care hospitals in 
as many diﬀerent European countries between June 2007 and June 2008. All 
hospitals were participating in the EARSS and were selected on the basis of reliable 
diagnostic quality of their microbiological laboratories and representative levels 
of resistance for their countries.6 Details can be found elsewhere.3,4
The cohorts consisted of patients with microbiologically conﬁrmed S. aureus or E. 
coli BSI. Patients were identiﬁed by daily liaison with the microbiological laboratory. 
Criteria for inclusion consisted of: i) ≥ 18 years, ii) mono-microbial BSI, iii) antibiotic 
therapy started after the index blood culture, iv) survival for at least one day after 
the index blood culture. 
Methods of data collection were described in detail elsewhere.3,4 The following 
individual information was collected between admission and the index blood 
culture: Date of admission, patient referral history (community, long-term care facility, 
nursing home or other hospital admission), frequent hospital exposure (deﬁned 
as two or more hospital admissions in the previous 12 months), type of admission 
(emergency or elective), surgery, presence of co-morbidities from the CCI7, and 
antibiotic therapy. Timing of the blood culture was recorded in hours and minutes, at 
the same day presence of indwelling devices (tracheal tube, central venous catheter, 
arterial vascular access, peripheral vascular access, urinary catheter, tracheostomy, 
nasogastric tube, wound drainage tube) and treatment in ICU were recorded. The 
anatomical origin of the BSI (in the case of secondary BSI) and the susceptibility 
proﬁle of the causative pathogen were extracted from the laboratory information 
system. All antibiotic regimens, administered after the positive blood culture, were 
registered, including time (hours and minutes) and date of administration. 
Empirical therapy was deﬁned as all therapy received within the ﬁrst two days after 
the index blood culture. Appropriate therapy was deﬁned as administration of an 
antibiotic compound for which the identiﬁed bacterial isolate showed clinical 
susceptibility as tested in vitro by the diagnostic laboratory. For MRSA and G3CREC 
class resistance against all beta-lactam agents, except carbapenems in the case of 
G3CREC, was assumed. The main outcome was mortality 30 days after the index 
blood culture with follow-up beyond hospital discharge.
This study complied with the Dutch patient conﬁdentiality regulations and ethical 























Statistical analyses were performed using SAS 9.1 and R 2.8.1. All analyses were 
performed separately for the S. aureus and E. coli cohort. For comparison of patient 
characteristics Chi-square or Mann-Whitney U tests were used for dichotomous 
and continuous variables. 
Kaplan-Meier curves were plotted to compare the time (in hours) to appropriate 
therapy between patients with MSSA versus MRSA, or those with a SEC versus 
G3CREC. The diﬀerence was tested by a signed log-rank test. 
The association between time, appropriate therapy and clinical outcome was 
illustrated in a bar chart, whereby mortality rates (per day) were calculated for 
each day since the index blood culture. Mortality rates were given separately for 
patients with and without appropriate therapy, whereby patients shifted from the 
“no appropriate therapy” group to the “appropriate therapy” group on the day 
appropriate therapy was initiated. The overall clinical eﬀectiveness of appropriate 
therapy was analysed by survival analysis. To adjust for the time between blood 
culture and appropriate therapy, appropriate therapy was included as a time-
dependent variable, thereby eliminating possible immortal time bias.5 Multivariate 
models were used to adjust for diﬀerences between patients with and without 
appropriate therapy. Variables were included if they changed the eﬀect estimate 
in bivariate regression by more than 5%. The likelihood ratio test was used to 
select the model with the best ﬁt by backward selection, whereby p<0.05 was 
considered signiﬁcant. Proportionality for all included variables was checked with 
the Wald test for time interaction. In the ﬁnal model, interaction was tested for all 
clinically relevant combinations. To correct for cluster eﬀects within hospitals we 
used stratiﬁed analysis when the estimate for appropriate therapy changed more 
than 5% after stratiﬁcation. For all estimates CI95 were reported.
Results
Between June 2007 and June 2008, relevant BSIs were recorded in 13 hospitals 
during 4,791,550 patient-days.3,4 Altogether, 1,000 and 1,328 patients were 
identiﬁed with S. aureus and E. coli BSIs, respectively. Of these 763 (76%) and 1,028 
(77%), fulﬁlled the inclusion criteria. 
In the S. aureus cohort, the median age was 68 (IQR, 55-77). Two hundred twenty-
eight of 763 (30%) patients had MRSA. The majority was male (466, 61%) and 
admitted through the emergency department (596, 78%). A large number of 
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patients had a central venous catheter (274, 36%), peripheral vascular access 
(558, 73%) or a urinary catheter (289, 38%) in place at the time when the BSI 
was diagnosed. The most commonly reported sources of BSI were intravascular 
catheters (207, 27%) or a skin or soft tissue infection (152, 20%). Patients with a 
delay in appropriate therapy of more than one day had stayed in hospital for longer 
before the BSI (5 days; IQR, 0-17 versus 1 day; IQR, 0-8; p<0.01), and had more often 
received antibiotic therapy prior to diagnosis (55% versus 37%, p=0.01). They also 
had a higher proportion of MRSA (61% versus 18%, p<0.01). 
In the E. coli cohort, the median age was 73 (IQR, 60-81). Ninety-ﬁve of 1,028 (9%) 
patients had G3CREC BSI. The majority was female (575, 56%). Eight hundred 
forty-six patients (82%) were emergency admissions and a large number had a 
peripheral vascular access (797, 78%) or a urinary catheter (420, 41%) at the time 
the diagnostic blood culture was taken. The most common source of BSI was the 
urinary tract (148, 14%). Similar to the patients in the S. aureus cohort, patients 
with a delay in appropriate therapy of more than one day also had had a longer 
admission period before the BSI (1 day; IQR, 0-9 versus 0 days; IQR, 0-5; p<0.01), 
more often had received antibiotic therapy prior to the bacteraemic episode (97, 
49% versus 298, 36%, p=0.05) and the proportion of E. coli isolates expressing 
third-generation cephalosporin resistance was higher (22% versus 6%, p<0.01; 
Table 1)
Appropriate therapy
Five hundred ﬁfty-ﬁve of 763 (73%) patients with S. aureus BSI received appropriate 
therapy within the ﬁrst day after the index blood culture, after two days this 
number increased to 623 (82%) patients. Altogether, 697/763 (91%) patients with 
S. aureus BSI received appropriate therapy within 14 days. 
For patients with MRSA and MSSA BSI the time to appropriate therapy diﬀered 
signiﬁcantly (log-rank test, p<0.01). Figure 1A shows the diﬀerence in the ﬁrst 72 
hours, based on 569/763 patients for whom exact data on the timing of blood 
culture and therapy were available. The median delay was 4 hours (IQR, 1-24) for 
MSSA patients versus 48 hours (IQR, 12-96) for MRSA patients (Figure 1A; log-rank 
test, p<0.01). Overall, 96% (CI95, 94-97%) of the patients with MSSA BSI received 
appropriate therapy compared to 82% (CI
95
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Figure 1. Kaplan-Meier curves with time to appropriate therapy for patients with MSSA or MRSA 























Eight hundred-thirty of 1,028 (81%) patients with an E. coli BSI received appropriate 
therapy within the ﬁrst day after the blood culture, after two days this increased to 
909 (88%) patients. Overall, 957/1,028 (93%) of the patients with E. coli BSI received 
appropriate therapy within 9 days. In this cohort, presence of third-generation 
cephalosporin resistance increased the time to appropriate therapy as well (log-
rank test, p<0.01). Based on 779/1,028 patients with data about the exact timing of 
blood culture and therapy, the median delay for patients with SEC BSI was 4 hours 
(IQR, 0-26) versus 40 hours (IQR, 3-73) for the G3CREC patients (Figure 1B; log-rank 
test, p<0.01). Overall, 94% (CI95, 92-95%) of the patients with SEC BSIs received 
appropriate therapy compared to 85% (CI
95
, 78-92%) of the G3CREC patients (X2, 
p<0.01).
Thirty-day mortality
In the S. aureus cohort, 30/763 (4%) patients were lost-to-follow-up after being 
discharged alive. From the remaining 733 patients with S. aureus BSI 172 (23%) 
died within 30 days after the index blood culture. In the group of patients receiving 
appropriate therapy, 124 of 669 (22%) patients died, compared to 27/64 (42%) 
patients without appropriate therapy. For patients with MSSA BSI and appropriate 
therapy, 92/486 (19%) died after a median of 7 days, while 10/23 (43%) without 
appropriate therapy died after a median of three days. In the MRSA group, 53/183 
(29%) patients with appropriate therapy died after a median of 9 days, and 17/41 
(41%) patients without appropriate therapy died after a median of two days. 
In Figure 2, mortality rates for day one to 30 are shown. Most patients without 
appropriate therapy died in the ﬁrst days after the index blood culture, when the 
proportion of patients without appropriate therapy is largest. As a consequence, 
the incidence of mortality per day is only slightly larger for patient without 
appropriate therapy versus those with appropriate therapy, especially in the MRSA 
cohort.
In the E. coli cohort, 49/1,028 (5%) were lost-to-follow-up after being discharged 
alive. From the remaining patients 151/979 (15%) died within 30 days. For patients 
receiving appropriate therapy, 126/912 (14%) died, compared to 25/67 (37%) 
without appropriate therapy. For patients with SEC BSI and appropriate therapy, 
103/833 (12%) died after a median of 30 days and 18/53 (34%) without appropriate 
therapy after a median of 13 days. In the group of patients with G3CREC BSI and 
appropriate therapy, 23/79 (29%) died after a median of 9 days, while 7/14 (50%) 
without appropriate therapy died after a median of 8 days. The mortality rate per 
78
day for SEC and G3CREC showed the same pattern as for the MSSA and MRSA 
cohorts, respectively.
Since methicillin resistance in S. aureus BSI and third-generation cephalosporin 
resistance in E. coli BSI were strongly related with delay in appropriate therapy, 
diﬀerent survival models were created for patients with MSSA, MRSA, SEC or 
G3CREC BSI. In addition, cluster eﬀects at hospital level changed the eﬀect estimate 
more than 5% and therefore hospital was included as stratum variable.
Survival models, adjusted for immortal time bias by including appropriate therapy 
as a time-dependent variable5, showed that appropriate therapy decreased 30-
day mortality in the group of patients with MSSA BSI (HR, 0.47; CI
95
, 0.23-0.95) and 
SEC BSI (HR, 0.44; CI
95
, 0.26-0.75). In the MRSA and G3CREC cohorts the HRs for 
appropriate therapy were close to one and insigniﬁcant (MRSA HR, 1.01, CI
95
, 0.56-
1.83; G3CREC, HR, 1.20, CI
95
, 0.48-2.99). Multivariate analyses gave similar results as 
the univariate analysis, appropriate therapy signiﬁcantly reduced 30-day mortality 
in the MSSA (HR, 0.34; CI
95
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Mortality rate per patient day
Day 1 2 3 4-5 6-10 11-20 21-30
Appropriate 
therapy




0.04 0.05 0.09 0.00 0.00 0.01 0.01
p-value 0.53 0.43 0.17 0.99 0.99 0.59 0.58
















1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Days since index blood culture
Mortality rate per patient day
Day 1 2 3 4-5 6-10 11-20 21-30
Appropriate therapy 0.04 0.02 0.03 0.02 0.01 0.01 0.01
Without appropriate 
therapy
0.06 0.03 0.02 0.00 0.01 0.01 0.01
p-value 0.82 0.93 0.88 0.74 0.99 0.99 0.99
Figure 2. Mortality rate for each day since the index blood culture, for patients with and without 
appropriate therapy at that moment in time, plotted separately for patients with MSSA BSI (A) 
or MRSA BSI (B).
B
80
Table 2. Hazard ratios for the impact of appropriate therapy received within two days after 
infection (empirical) or independent of timing, on 30-day mortality for patients with MSSA and 
MRSA, SEC and G3CREC BSI.a







0.58 (0.32-1.05) 0.56 (0.30-1.04) Age, urinary catheter, 
intubation




1.01 (0.61-1.68) 1.12 (0.65-1.94) Urinary catheter, intubation, 
CCI




0.47 (0.29-0.75) 0.47 (0.28-0.77) Intubation, CCI,
LOS before infection




1.59 (0.65-3.85) 1.24 (0.46-3.31) Age, intubation, CCI, severe 
liver disease, interaction age 
and Charlson scoreAppropriate therapy 1.20 (0.48-2.99) 0.94 (0.29-3.10)
N, number of patients included in the analysis
a Based on Cox’s regression analysis with appropriate therapy included as time-dependent 
variable
Discussion
In clinical settings, where an experimental study is prohibited for ethical reasons, 
an observational study is the only way to quantify the impact of appropriate 
therapy. As a consequence, acknowledgement of possible confounding and bias 
is essential. This study conﬁrmed that patients with MRSA or G3CREC infections 
experienced signiﬁcantly longer waiting times till appropriate therapy was 
administered compared to patients infected by susceptible bacteria. Therefore, 
we analysed the impact of appropriate therapy separately for MSSA, MRSA, SEC 
and G3CREC BSIs. Taking into account timing of therapy, appropriate therapy 
was associated with a signiﬁcantly improved survival for patients with MSSA BSI 
(HR 0.47; CI95, 0.23-0.95) or SEC BSI (HR, 0.44; CI95, 0.26-0.75). For the two resistant 
cohorts an impact of appropriate therapy could not be ascertained. 





















patients from thirteen diﬀerent tertiary care centres spread over Europe. Variation 
in resistance endemicity, for MRSA ranging from 7% to 56% and for G3CREC from 
4% to 24% 6, suggests that the outcomes from this study are representative for 
the situation in Western and Central Europe. Second, mortality was not measured 
at discharge, but after a predeﬁned interval of 30 days after ascertainment of 
infection, including follow-up beyond hospital discharge, preventing informative 
censoring. Third, survival analysis was used, with appropriate therapy included as 
a time-dependent variable. In this way, the spurious positive association between 
longer pre-treatment survival, a higher likelihood of receiving appropriate therapy 
and longer post-treatment survival was eliminated from the analysis.5 This was 
especially important in the cohorts of patients with infections due to resistant 
micro-organisms, because time from blood culture to appropriate therapy was 
longer in these groups. Finally, the appropriateness of therapy was not based 
on subjective judgments, but based on the objective measurement of in vitro 
susceptibility and accepted rules of beta-lactam class resistance of the isolated 
pathogen.
Other studies conﬁrm that patients with infections complicated by resistance are 
faced with prolonged delays in administration of appropriate therapy.8,9 However, 
so far there is no consensus about the clinical eﬀectiveness of therapy. Most 
studies included inappropriate therapy as a risk factor for mortality, whereby some 





, 2.8-114.5)11, others could not conﬁrm higher mortality rates.8,12-14 
These diﬀerences can be explained by inclusion of varying populations, whereby 
the consequences of inappropriate therapy tend to be pronounced for severely ill 
patients.9,11,15-18 Part of these diﬀerences may also be related to varying degrees of 
bias; only few of the above referenced studies included follow-up beyond hospital 
discharge9,13,15, just one analysed the impact of therapy separately for resistant and 
susceptible cases19, and none of previously published studies analysed therapy as 
time-dependent factor in survival analysis.
Although the association between appropriate therapy and improved survival 
may seem intuitive, there are several, possible explanations why we did not ﬁnd 
the same association for patients with resistant infections. A limitation of this study 
was lack of data about dosing and serum levels, especially for vancomycin, but 
we accepted this trade oﬀ as a concession to this international multi-centre study 
design. An alternative, methodological explanation for the absence of an eﬀect 
in the resistant cohorts may be a lack of power; i.e. the number of cases might 
have been too low to be able to detect a weak association. This would be true 
82
if the beneﬁt of appropriate therapy over inactive therapy was small, as may be 
the case for MRSA infections. Vancomycin, the most important active antibiotic for 
MRSA patients, may be inferior to beta-lactam antibiotics active against MSSA.20,21 
At the other end, treatment of MRSA with beta-lactam antibiotics, not deemed 
eﬀective, may still have some residual eﬀect.22 Finally, timing of therapy could 
have inﬂuenced the potentially beneﬁcial eﬀect. Previous studies have shown that 
most fatalities among bacteraemic patients occur within the ﬁrst two days23,24, 
indicating that there is a limited window of opportunity for therapy. Patients 
initially treated inappropriately are faced with an increasing microbial burden, 
increasing inﬂammatory cellular dysfunction and tissue injury, which can lead to 
shock and once irreversible organ injury is present, death is inevitable.23,25 In this 
study less than 50% of the patients in the resistant cohorts received appropriate 
therapy within the ﬁrst two days and most patients dying without appropriate 
therapy died in this period. This suggests that for those patients who could beneﬁt 
most from appropriate therapy, initiation of appropriate therapy was too late. 
To conclude, most patients suﬀering from susceptible S. aureus and E. coli BSIs 
are treated timely and eﬀectively in European hospitals. For patients aﬀected by 
resistant infections, the often delayed appropriate therapy was not improving 
survival. This study stresses the importance of early, adequate empirical treatment 
of septicaemic patients. And the results underline the value of local surveillance 
of antimicrobial resistance in combination with demographic and clinical data in 
order to improve the choice of antibiotic compounds in the individual patient.
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